Starling Oncology (STLNW) Net Equity Issued and Repurchased (2022 - 2025)

Starling Oncology (STLNW) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $3.9 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $3.9 million; the trailing twelve-month figure through Dec 2025 stood at $18.0 million (changed N/A YoY), and the FY2025 full-year result was $13.8 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased retreated to $3.9 million in Q4 2025 per STLNW's latest filing, from $11.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $11.8 million in Q3 2025 and bottomed at -$75000.0 in Q3 2024.
• Historically, Net Equity Issued and Repurchased has averaged $1.8 million across 4 years, with a median of $96000.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased plunged 676.92% in 2024, then jumped 110050.0% in 2025.
• Over 4 years, Net Equity Issued and Repurchased stood at $79000.0 in 2022, then surged by 43.04% to $113000.0 in 2023, then sank by 166.37% to -$75000.0 in 2024, then soared by 5285.33% to $3.9 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $3.9 million, $11.8 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.